A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)
Status:
Recruiting
Trial end date:
2027-09-01
Target enrollment:
Participant gender:
Summary
This is a single-arm, non-randomized, open-label Phase 2 therapeutic study that will assess
the effects of adding BPM31510 onto a conventional treatment framework of RT and concurrent
TMZ chemotherapy for subjects with newly diagnosed glioblastoma.